Publications in OpenAlex of which a co-author is affiliated to this organization
All publications | By field | By subfield
All publications [Next]
| Title | DOI |
|---|---|
| https://doi.org/10.1038/mi.2009.116 | Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis |
| https://doi.org/10.1016/j.chom.2012.02.006 | Lactocepin Secreted By Lactobacillus Exerts Anti-Inflammatory Effects By Selectively Degrading Proinflammatory Chemokines |
| https://doi.org/10.1172/jci60530 | Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice |
| https://doi.org/10.1016/j.mib.2013.06.002 | Engineering lactococci and lactobacilli for human health |
| https://doi.org/10.1007/s12035-011-8175-3 | Role of the 5-HT7 Receptor in the Central Nervous System: from Current Status to Future Perspectives |
| https://doi.org/10.2337/db13-1236 | Oral Delivery of Glutamic Acid Decarboxylase (GAD)-65 and IL10 byLactococcus lactisReverses Diabetes in Recent-Onset NOD Mice |
| https://doi.org/10.1258/la.2009.009112 | Surface area assessment of the murine intestinal tract as a prerequisite for oral dose translation from mouse to man |
| https://doi.org/10.1016/j.oraloncology.2010.04.008 | AG013, a mouth rinse formulation of Lactococcus lactis secreting human Trefoil Factor 1, provides a safe and efficacious therapeutic tool for treating oral mucositis |
| https://doi.org/10.1002/cncr.28365 | Phase 1b, multicenter, single blinded, placebo‐controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy |
| https://doi.org/10.4049/jimmunol.0802891 | Induction of Antigen-Specific Tolerance by Oral Administration of Lactococcus lactis Delivered Immunodominant DQ8-Restricted Gliadin Peptide in Sensitized Nonobese Diabetic Ab° Dq8 Transgenic Mice |
| https://doi.org/10.1186/1475-2859-13-s1-s11 | Recombinant Lactococcus lactis can make the difference in antigen-specific immune tolerance induction, the Type 1 Diabetes case |
| https://doi.org/10.1111/j.1749-6632.2009.05067.x | Actobiotics™ as a Novel Method for Cytokine Delivery |
| https://doi.org/10.3109/08830180903197498 | Modulation of Gut-Associated Lymphoid Tissue Functions with Genetically ModifiedLactococcus lactis |
| https://doi.org/10.2741/3571 | Immunomodulation by genetically engineered lactic acid bacteria |
| https://doi.org/10.1111/j.1365-2613.2008.00598.x | Expression of galectins‐1, ‐3 and ‐4 varies with strain and type of experimental colitis in mice |
| https://doi.org/10.1111/j.1365-3083.2008.02206.x | Genetically Engineered Lactococcus lactis Secreting Murine IL‐10 Modulates the Functions of Bone Marrow‐Derived Dendritic Cells in the Presence of LPS |
| https://doi.org/10.3920/bm2014.0083 | Trimming of two major type 1 diabetes driving antigens, GAD65 and IA-2, allows for successful expression in Lactococcus lactis |
| https://doi.org/10.1111/j.1742-4658.2012.08581.x | Biochemical and pharmacological study of N‐linked glycosylation of the human serotonin 5‐HT7(a) receptor |
| https://doi.org/10.1200/jco.2009.27.15_suppl.e14570 | Effect of a mouth rinse formulation with human trefoil factor 1-secreting Lactococcus lactis in experimental oral mucositis in hamsters |
| https://doi.org/10.1109/biorob52689.2022.9925448 | Experimental Evaluation of a Stiffness-Fault-Tolerant Control Strategy on an Elastic Actuator for Wearable Robotics |
| https://doi.org/10.1136/gutjnl-2014-307263.177 | PTU-103 Intra-luminal Interleukin (il)-27 Is A Potential Future Therapeutic For Inflammatory Bowel Disease |
| https://doi.org/10.1586/eci.12.55 | Clinical development of lactocepin: a novel bacterial biologic? |
| https://doi.org/10.1016/j.cyto.2013.06.115 | 112 |
| https://doi.org/10.1016/j.cyto.2010.07.099 | PS1-27 Lactococcus lactis expressing IL-27: A potential therapeutic for inflammatory bowel disease |
| https://doi.org/10.1016/j.cyto.2010.07.048 | SS1-1 Lactococcus lactis expressing IL-27: Therapeutic promise in inflammatory bowel disease |
| https://doi.org/10.1016/j.clim.2009.03.083 | OR.71. Combination Therapy of Short-term Low-dose Anti-CD3 and Oral Administration of Genetically-modified Lactococcus Lactis Secreting Insulin and IL-10 Enhances Remission in New-onset Diabetic NOD Mice |
| https://doi.org/10.1097/00054725-201212001-00209 | Mucosal Delivery of IL-27 Attenuates Murine Enterocolitis via T Cell-Derived IL-10 |
| https://doi.org/10.1200/jco.2012.30.15_suppl.9024 | Phase Ib, multicenter, single-blinded, placebo-controlled, sequential dose-escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer (LAHNC) receiving induction chemotherapy (ICT). |